Mesoblast Limited
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Silviu Itescu
- Full Time Employees
- 108
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 55 Collins Street Melbourne VIC Australia 3000
- IPO Date
- Dec 21, 2004
- Website
- mesoblast.com
- Similar Companies
- Business
- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) is a commercial-stage biotechnology company that develops and commercializes allogeneic cellular medicines derived from its proprietary mesenchymal lineage cell technology platform for the treatment of severe inflammatory conditions with high unmet medical needs; its lead products include Remestemcel-L (Ryoncil), the first and only FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in pediatric patients two months of age and older, Revascor (rexlemestrocel-L) for advanced chronic heart failure, and MPC-06-ID (rexlemestrocel-L) for chronic low back pain due to degenerative disc disease; the company also advances Remestemcel-L for moderate to severe acute respiratory distress syndrome and maintains an emerging pipeline of next-generation therapies. Founded in 2004 and headquartered at 55 Collins Street, Level 38, Melbourne, Australia, Mesoblast operates primarily in Australia, the United States, and Singapore, targeting patients with complex diseases resistant to standard care through off-the-shelf cellular therapies that promote tissue repair, modulate immune responses, and enable industrial-scale manufacturing without donor-recipient matching. Recent developments include the successful U.S. commercial launch of Ryoncil with $20 million in gross revenue for the quarter ending June 30, 2025, addition to the S&P/ASX 200 Index effective March 6, 2025, and alignment with the U.S. FDA on requirements for a Biologics License Application filing for Revascor to accelerate potential approval in heart failure.
Company News
Mesoblast: Ryoncil Helps Fund Rexlemestrocel-L For Back Pain
Mesoblast (NASDAQ:MESO) Stock Price Breaks Below 50 Day Moving Average – Should You Sell?
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
Mesoblast (NASDAQ:MESO) and Biogen (NASDAQ:BIIB) Head-To-Head Contrast
Mesoblast (NASDAQ:MESO) Share Price Passes Above 50 Day Moving Average – Time to Sell?
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
Mesoblast Reports Substantial Revenue Growth to US$120M
Mesoblast H2 Earnings Call Highlights
MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million